SABI Mind and Reverie Psychedelics have partnered to expand research into psychedelic-assisted therapies.
SABI Mind (SABI) has announced Canada’s first research partnership with US-based Reverie Psychedelics.
The collaboration will provide academics and psychedelic companies researching psychedelic therapies access to SABI clinics, qualified clinical staff, and Reverie’s expanding suite of clinical trial support services as these novel treatments work their way through the rigorous drug development process.
Robert Wallace, Founder and CEO of Reverie, commented: ”I am elated to have the opportunity to work alongside the outstanding team and research-experienced physicians and staff at SABI.
”This is our first Canadian clinical research partnership and will provide researchers from Canada, the US and around the globe with qualified clinical trial sites and SABI patients with access to emerging psychedelic treatment options.”
Having developed and co-ordinated the Canadian Psychedelic Survey (CPS), SABI has already established itself as an academic leader in the psychedelic treatment space. This collaboration with Reverie will support and expand SABI’s clinical trial goals and capabilities.
“While there is a growing amount of evidence regarding the safety and efficacy of psychedelic-assisted therapies, this is the dawn of the Renaissance in psychedelic drug research and development,” says Philippe Lucas Ph.D., President of SABI Mind.
“Dozens of companies and academic institutions are currently developing psychedelic medicines, and SABI is pleased to partner with the skilled and experienced team at Reverie to support research into novel psychedelic-based treatments and expand our understanding of how they might improve the health and quality of life of chronically ill patients around the world.”
